CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $2.38B, above the global median of $1.15B
- FinancialsAltman Z-Score 10.81: safe zone
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.38BUSDvs all stocks (USD)
Trailing P/E
108.47xvs Biotechnology peers
Revenue (TTM)
292.09MUSDvs all stocks (USD)
Profit Margin
7.35%vs Biotechnology peers
Beta
1.07xvs all stocks
52-Week Change
31.53%vs all stocks
Market Capitalization
2.38BUSDvs all stocks (USD)
Enterprise Value
2.33BUSDvs all stocks (USD)
Trailing P/E
108.47xvs Biotechnology peers
Forward P/E
54.74xvs Biotechnology peers
PEG Ratio
-2.27xvs Biotechnology peers
Price to Sales (TTM)
8.15xvs Biotechnology peers
Price to Book (MRQ)
6.68xvs Biotechnology peers
Enterprise to Revenue
7.98xvs Biotechnology peers
Enterprise to EBITDA
83.58xvs Biotechnology peers
Gross Margin
72.00%vs Biotechnology peers
Profit Margin
7.35%vs Biotechnology peers
Operating Margin
-11.79%vs Biotechnology peers
Return on Assets (TTM)
2.17%vs Biotechnology peers
Return on Equity (TTM)
6.59%vs Biotechnology peers
Revenue (TTM)
292.09MUSDvs all stocks (USD)
Revenue per Share (TTM)
5.78USDUpdated Jul 19, 2026Quarterly Revenue Growth
30.10%vs Biotechnology peers
Gross Profit (TTM)
218.59MUSDvs all stocks (USD)
EBITDA (TTM)
29.55MUSDvs all stocks (USD)
Net Income (TTM)
21.46MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
30.09%vs Biotechnology peers
Operating Cash Flow (TTM)
61.69MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
42.37MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
276.26MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
70.66MUSDFY2025 · Dec 31, 2025Gross Profit
205.60MUSDFY2025 · Dec 31, 2025Operating Income
11.04MUSDvs all stocks (USD)
Pre-tax Income
17.38MUSDFY2025 · Dec 31, 2025Income Tax Expense
859.00KUSDFY2025 · Dec 31, 2025Net Income
16.52MUSDFY2025 · Dec 31, 2025EBIT
18.01MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
29.55MUSDFY2025 · Dec 31, 2025Research & Development
27.56MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
166.99MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
7.01MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
630.00KUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
16.52MUSDFY2025 · Dec 31, 2025Operating Cash Flow
48.88MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
100.09MUSDFY2025 · Dec 31, 2025Income Tax Paid
580.00KUSDFY2025 · Dec 31, 2025Interest Paid
489.00KUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
16.52MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
11.54MUSDFY2025 · Dec 31, 2025Stock-based Compensation
38.77MUSDFY2025 · Dec 31, 2025Other Non-cash Items
5.58MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-23.26MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
2.97MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-3.24MUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
0.00USDFY2025 · Dec 31, 2025Purchase of Investments
-72.37MUSDFY2025 · Dec 31, 2025Sale of Investments
55.60MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-16.77MUSDFY2025 · Dec 31, 2025Other Financing Charges
-6.86MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
7.07MUSDFY2025 · Dec 31, 2025Shares Outstanding
51.01MSharesUpdated Jul 19, 2026Float Shares
50.44MSharesUpdated Jul 19, 2026Shares Short
4.91MSharesUpdated Jul 19, 2026Short Ratio
6.61daysvs all stocks
Short % of Shares Outstanding
12.40%vs all stocks
% Held by Insiders
1.19%vs all stocks
% Held by Institutions
113.67%vs all stocks
Total Cash (MRQ)
145.34MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
2.85USDUpdated Jul 19, 2026Total Debt (MRQ)
95.04MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.2668xvs Biotechnology peers
Current Ratio (MRQ)
5.18xvs Biotechnology peers
Book Value per Share (MRQ)
6.98USDUpdated Jul 19, 2026Total Assets
487.97MUSDvs all stocks (USD)
Total Current Assets
247.44MUSDFY2025 · Dec 31, 2025Total Liabilities
133.33MUSDFY2025 · Dec 31, 2025Total Non-current Assets
240.53MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
84.18MUSDFY2025 · Dec 31, 2025Total Current Liabilities
49.15MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
100.09MUSDFY2025 · Dec 31, 2025Other Short-term Investments
37.41MUSDFY2025 · Dec 31, 2025Accounts Receivable
84.63MUSDFY2025 · Dec 31, 2025Inventory
17.56MUSDFY2025 · Dec 31, 2025Accounts Payable
15.83MUSDFY2025 · Dec 31, 2025Short-term Debt
14.09MUSDFY2025 · Dec 31, 2025Long-term Debt
82.28MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
1.90MUSDFY2025 · Dec 31, 2025Common Stock (Book)
730.66MUSDFY2025 · Dec 31, 2025Retained Earnings
-376.30MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
354.64MUSDvs all stocks (USD)
52-Week Low
28.95USDUpdated Jul 19, 202652-Week High
48.75USDUpdated Jul 19, 202652-Week Change
31.53%vs all stocks
Beta
1.07xvs all stocks
50-Day MA
39.24USDUpdated Jul 19, 2026200-Day MA
36.72USDUpdated Jul 19, 2026Avg 10-Day Volume
477.62KSharesUpdated Jul 19, 2026Avg 30-Day Volume
652.70KSharesUpdated Jul 19, 2026Diluted EPS (TTM)
0.4300USDUpdated Jul 19, 2026Other Income / Expense
-44.00KUSDFY2025 · Dec 31, 20253 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
Revenue Growing With Receivables Growing
Revenue has risen three years, and what customers owe has risen with it.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.72Profit Margin: 0.07
Financial Health
Altman Z-Score 10.81: safe zoneNotable
Altman Z-Score: 10.81
High earnings qualityNotable
Earnings Quality Score: 2.14
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $2.38B, above the global median of $1.15BNotable
Market cap (USD): 2,381,822,153Global Median: 1,146,734,693.424
Levered free cash flow is $42.37M, above the global median of $16.24MNotable
Levered free cash flow (USD): 42,369,376Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
BrightGene Bio-Medical Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Mineralys Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Pell Bio-Med Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Prestige Consumer Healthcare Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Nurix Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
BioCryst Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Biohaven Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Pharvaris N.V.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Nektar Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Harmony Biosciences Holdings, Inc.
3 interpretationsIndustry-Benchmarked ROA and Margin ElevatedIndustry-Benchmarked Return on Capital ElevatedRevenue Growing With Receivables Growing
Trane Technologies plc
3 interpretationsIndustry-Benchmarked ROA and Margin ElevatedIndustry-Benchmarked Return on Capital ElevatedRevenue Growing With Receivables Growing
XPEL, Inc.
3 interpretationsIndustry-Benchmarked ROA and Margin ElevatedIndustry-Benchmarked Return on Capital ElevatedRevenue Growing With Receivables Growing